These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

88 related items for PubMed ID: 3989212

  • 21. [Value of inserts in the treatment of dry eye syndromes (preliminary results)].
    Huguet P, Colin J, Renard G.
    Bull Soc Ophtalmol Fr; 1981 Dec; 81(12):1173-7. PubMed ID: 7343154
    [No Abstract] [Full Text] [Related]

  • 22. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
    Barber LD, Pflugfelder SC, Tauber J, Foulks GN.
    Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes.
    Willen CM, McGwin G, Liu B, Owsley C, Rosenstiel C.
    Eye Contact Lens; 2008 Jan; 34(1):43-5. PubMed ID: 18180683
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [A new therapy concept for the treatment of dry eye--the usefulness of phospholipid liposomes].
    Lee S, Dausch S, Maierhofer G, Dausch D.
    Klin Monbl Augenheilkd; 2004 Oct; 221(10):825-36. PubMed ID: 15499517
    [Abstract] [Full Text] [Related]

  • 26. Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients.
    Hom MM.
    Eye Contact Lens; 2006 Mar; 32(2):109-11. PubMed ID: 16538135
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [A new therapeutic presentation : inserts and their indications in dry eye syndromes].
    Deschamps F, Montard M, Royer J.
    Bull Soc Ophtalmol Fr; 1982 Mar; 82(6-7):889-90. PubMed ID: 7172391
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Conservative treatment of meibomian gland dysfunction.
    Romero JM, Biser SA, Perry HD, Levinson DH, Doshi SJ, Terraciano A, Donnenfeld ED.
    Eye Contact Lens; 2004 Jan; 30(1):14-9. PubMed ID: 14722463
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Compliance with and typical usage of artificial tears in dry eye conditions.
    Swanson M.
    J Am Optom Assoc; 1998 Oct; 69(10):649-55. PubMed ID: 9805446
    [Abstract] [Full Text] [Related]

  • 35. Effect of osmolarity of artificial tear drops on relief of dry eye symptoms: BJ6 and beyond.
    Wright P, Cooper M, Gilvarry AM.
    Br J Ophthalmol; 1987 Feb; 71(2):161-4. PubMed ID: 3548809
    [Abstract] [Full Text] [Related]

  • 36. Color discrimination in patients with keratoconjunctivitis sicca before and after artificial tear application.
    Rieger G.
    Wien Klin Wochenschr; 1998 Apr 24; 110(8):296-7. PubMed ID: 9615962
    [Abstract] [Full Text] [Related]

  • 37. Comparative study of tear substitutes and their immediate effect on the precorneal tear film.
    Avisar R, Creter D, Levinsky H, Savir H.
    Isr J Med Sci; 1997 Mar 24; 33(3):194-7. PubMed ID: 9313790
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Comparison of the efficacy of two lipid emulsion eyedrops in increasing tear film lipid layer thickness.
    Scaffidi RC, Korb DR.
    Eye Contact Lens; 2007 Jan 24; 33(1):38-44. PubMed ID: 17224677
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.